“We have saved a tremendous amount of paper pushing time by using ExpenseWatch.com. We no longer have an employee walking purchase orders around the office for signatures – now everyone can simply log in and approve!”

Lin Moody,
Director, Finance & Administration

 

About CyThera Inc.

 

 

CyThera Issues

  • Efficiency: CyThera needed to make its requisition process as efficient as possible. Time wasted pushing paper was a big problem.
  • Company Size: As a small research and development company, CyThera needed a cost-effective operating expense control system.
  • Manual Processes: Prior to ExpenseWatch.com, CyThera used a proprietary FileMaker database for its requisitions. Employees tracked down signature approvals manually.

Operating Expense Goals

  • Paperless Systems: CyThera needed to create an efficient process to track procurement procedures. Eliminating the paper trail and handling net purchasing more efficiently was paramount. The company wanted to simplify the entire process to flow as smoothly as possible.
  • Improved Requisition Process: CyThera wanted a system that would allow it to submit an electronic requisition and check the status online. Submitting and reviewing requisitions needed to consume less time and money.

ExpenseWatch.com Solution

  • Automation: Instead of filling out piles of paper forms, users submit electronic requisitions and check the status online. This provides far more information and reduces the time needed for reviews.
  • Dynamic Solution with Automatic Upgrades: The ExpenseWatch.com online infrastructure allows for new features and enhancements to be added without burdening Cythera with expensive upgrades.

About CyThera Inc.
CyThera Inc. is a private biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative disease.

CyThera is developing a technology platform that has the potential to treat a wide range of human degenerative diseases ? these include liver disease, Parkinson’s disease, macular degeneration and stroke.

The Company’s initial focus is on pancreatic islet transportation for the treatment of diabetes.

< Complete case studies list | top ^